BACKGROUND: Associations between type 2 diabetic patients and a higher risk of developing cancer have been reported worldwide. Recently, a protective effect of metformin has been described. AIM: To examine in the Belgian primary care population the relation between presence of type 2 diabetes with and without metformin treatment and the occurrence of malignancies. DESIGN OF STUDY: Retrospective cohort study, based on the Intego database, an ongoing Belgian general practice-based morbidity registry, covering 90 general practitioners and including about 1.5 million patient-years between 1994 and 2008. METHOD: Cox proportional hazard analysis comparing emergence of malignancy in patients with and without type 2 diabetes, and among patients with diabetes comparing emergence of malignancy in those treated with various antidiabetic drugs. RESULTS: Malignancies occurred more in type 2 diabetic patients compared to non-diabetic controls (HR=1.84; 95% CI=1.51-2.24), adjusted for age, gender and weight. Treatment with both metformin and 'other' antidiabetic agents was related to decreased cancer risk (HR=0.24 and 0.22) compared to diet only in men but not in women. CONCLUSION: In this Belgian primary care setting, diabetic patients have higher cancer prevalences than non-diabetic patients. Moreover, in diabetic men, not only metformin but also other antidiabetic agents were associated with lower cancer risks.
BACKGROUND: Associations between type 2 diabeticpatients and a higher risk of developing cancer have been reported worldwide. Recently, a protective effect of metformin has been described. AIM: To examine in the Belgian primary care population the relation between presence of type 2 diabetes with and without metformin treatment and the occurrence of malignancies. DESIGN OF STUDY: Retrospective cohort study, based on the Intego database, an ongoing Belgian general practice-based morbidity registry, covering 90 general practitioners and including about 1.5 million patient-years between 1994 and 2008. METHOD: Cox proportional hazard analysis comparing emergence of malignancy in patients with and without type 2 diabetes, and among patients with diabetes comparing emergence of malignancy in those treated with various antidiabetic drugs. RESULTS:Malignancies occurred more in type 2 diabeticpatients compared to non-diabetic controls (HR=1.84; 95% CI=1.51-2.24), adjusted for age, gender and weight. Treatment with both metformin and 'other' antidiabetic agents was related to decreased cancer risk (HR=0.24 and 0.22) compared to diet only in men but not in women. CONCLUSION: In this Belgian primary care setting, diabeticpatients have higher cancer prevalences than non-diabeticpatients. Moreover, in diabeticmen, not only metformin but also other antidiabetic agents were associated with lower cancer risks.
Authors: Sara Gandini; Matteo Puntoni; Brandy M Heckman-Stoddard; Barbara K Dunn; Leslie Ford; Andrea DeCensi; Eva Szabo Journal: Cancer Prev Res (Phila) Date: 2014-07-01
Authors: Maria E Goossens; Frank Buntinx; Maurice P Zeegers; J H M Driessen; Marie L De Bruin; Frank De Vries Journal: Br J Clin Pharmacol Date: 2015-10-28 Impact factor: 4.335
Authors: Jessica K Paulus; Christina D Williams; Furha I Cossor; Michael J Kelley; Robert E Martell Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-05 Impact factor: 4.254
Authors: Furha Iram Cossor; Lucile L Adams-Campbell; Rowan T Chlebowski; Marc J Gunter; Karen Johnson; Robert E Martell; Anne McTiernan; Michael S Simon; Thomas Rohan; Robert B Wallace; Jessica K Paulus Journal: Cancer Epidemiol Date: 2013-06-15 Impact factor: 2.984
Authors: Maria E Goossens; Maurice P Zeegers; Marloes T Bazelier; Marie L De Bruin; Frank Buntinx; Frank de Vries Journal: BMJ Open Date: 2015-06-01 Impact factor: 2.692
Authors: Laura Deckx; Marjan van den Akker; Job Metsemakers; André Knottnerus; François Schellevis; Frank Buntinx Journal: J Cancer Epidemiol Date: 2012-08-23